Heart device follow-up study for high-risk heart patients
Part of Heart & circulation clinical trials.
This study monitors how well the AngelMed Guardian® System works after it has already been implanted. It focuses on people at higher risk of heart events, including those with diabetes or kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have at least one of these: diabetes, kidney function problems, or an elevated heart risk score
- You’ve had a recent serious heart event (like unstable angina, heart attack) or have had/planned bypass surgery within 6 months
- You’ve had a heart catheter procedure (coronary angiography) and treatment unless your doctor thinks implantation should happen sooner
- You live within about 60 minutes by ambulance of a hospital that can treat heart attacks
- You are age 21 or older, and if you can get pregnant you must have a negative pregnancy test or meet pregnancy-related conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a temporary heart pump (called the KARDION Cory P4) used during a high-risk angioplasty (stenting) procedure. The pump helps keep blood flowing in patients whose heart is weak or who have complex blockages, aiming to make the procedure safer.
This trial tests whether implanting a small device in the heart’s coronary sinus can reduce symptoms in people with long-lasting “refractory” angina despite taking the usual heart medicines. It may help improve how much activity you can do and reduce angina-related limitations.
This study tests a new way of monitoring people who have heart devices like pacemakers or defibrillators. Your care team will use remote data to track your heart and may be able to catch problems sooner, which could help you stay healthier.
This study checks how safe a small heart-pressure monitoring device is for people with advanced heart failure and severe kidney problems. It looks at whether doctors can continuously track heart filling/pressure to help manage symptoms and reduce risks.
This study checks how well specific MicroPort CRM heart devices and leads work in real life over time. If you already have one of these FDA/market-approved implants and can be followed yearly, the study helps the company monitor safety and performance.
This study tests whether a CardioPulmonary Management (CPM) system device used at home is safe and can improve outcomes for people with chronic heart failure. It may help manage symptoms and reduce complications, especially for higher-risk patients.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.